The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
NCT ID: NCT05035589
Last Updated: 2023-04-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2021-09-20
2021-11-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Molecular Subtype-Specific Mechanisms and Therapeutic Strategies in Sepsis
NCT06287684
Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection
NCT04600141
Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19
NCT04352985
Biomarkers in Exhaled Breath Condensates of Septic Patients to Predict Development of Multi-organ Dysfunction Syndrome
NCT01503684
Lactate Kinetics in Septic Shock
NCT05349370
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The following parameters will be collected from medical records:
* procalcitonin levels, daily for twenty days or until discharge or death.
* namely white cell count (WCC), neutrophils, lymphocytes,
* C-reactive protein (CRP)
* PaO2/FiO2 ratio (P/F ratio).
This group will be compared to a control group was chosen from patients admitted to the ICU who were not eligible for tocilizumab treatment, matched to the study group for age, gender, mode of ventilation required and length of stay in ICU.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TCZ
The first 50 patients admitted to the ITU at Mater Dei Hospital with COVID-19 Pneumonia, to whom tocilizumab was administered
Tocilizumab
Tocilizumab administered at a dose of 8mg/kg up to a maximum of 800mg
Control
50 patients admitted to ITU at Mater Dei Hospital with COVID-19 Pneumonia, who did not receive Tocilizumab
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tocilizumab
Tocilizumab administered at a dose of 8mg/kg up to a maximum of 800mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Admitted to ITU
* Tocilizumab treatment
Exclusion Criteria
16 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mater Dei Hospital, Malta
OTHER
Sciberras, Stephen M.D.
INDIV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Stephen Sciberras
Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mater Dei Hospital
Msida, , Malta
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MDHITU-TCZ
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.